Business Context and Reporting Period
This Form 8-K is a current report filed by Halozyme Therapeutics, Inc. on February 13, 2025, regarding an event that occurred on February 11, 2025. The filing addresses corporate governance changes involving the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the departure of a director:
- Connie L. Matsui, a member of the Board of Directors, notified the Company of her intention not to stand for reelection at the 2025 annual meeting of stockholders.
- Ms. Matsui served on the Board for nearly 18 years.
- The resignation was not the result of any disagreement with the Company regarding operations, policies, practices, strategy, management, or the Board.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, management commentary on financial performance, or discussion of risks and contingencies beyond the standard disclosure regarding the director's departure.
Key Facts for Investor Verification
- Connie L. Matsui will not seek reelection at the 2025 annual meeting.
- The departure is voluntary and amicable, with no stated disagreements.
- The Company has not yet announced a replacement nominee in this filing.
- Investors should monitor the upcoming 2025 annual meeting proxy statement for the final slate of director nominees.